AVIADOBIO LTD
Operating as AviadoBio, the venture-backed biopharmaceutical company develops targeted medicines and therapies for patients with neurodegenerative disorders, specifically frontotemporal dementia and amyotrophic lateral sclerosis.
Get an alert when AVIADOBIO LTD files next
Leroy will email you the moment a new filing lands at Companies House — one short note per filing, nothing else.
Cash
£31m
-34.9% vs 2024
Net assets
£27m
-24.7% lowest in 3 filed years
Employees
57
-12.3% lowest in 3 filed years
Profit before tax
-£13m
+38.2% highest in 3 filed years
Watchouts
Facts from the Companies House register and the latest accounts — not a rating
-
Material uncertainty over going concern
As the group and parent company are reliant on further funding which is not secured this indicates the existence of a material uncertainty which may cast significant doubt over the group and parent company's ability to continue as going concerns
-
Going-concern uncertainty disclosed
Net assets
3-year trend · vs Health Care median
Accounts
3-year trend · Δ = latest vs prior filed period · latest reflected 2025-12-31
| Metric | Trend | 2023-12-31 | 2024-12-31 | 2025-12-31 | Δ vs prior |
|---|---|---|---|---|---|
| Turnover | — | £2,371,625 | £16,148,347 | +580.9% | |
| Operating profit | -£22,725,259 | -£22,302,835 | -£14,588,254 | +34.6% | |
| Profit before tax | -£22,315,481 | -£21,684,439 | -£13,401,931 | +38.2% | |
| Net profit | -£19,119,174 | -£18,104,401 | -£10,122,842 | +44.1% | |
| Cash | £28,188,800 | £47,190,003 | £30,725,850 | -34.9% | |
| Total assets less current liabilities | £30,586,307 | £41,964,442 | £29,308,007 | -30.2% | |
| Net assets | £30,586,307 | £36,277,183 | £27,326,738 | -24.7% | |
| Equity | £30,586,307 | £36,277,183 | £27,326,738 | -24.7% | |
| Average employees | 64 | 65 | 57 | -12.3% | |
| Wages | £8,289,148 | £8,724,844 | £8,522,136 | -2.3% | |
| Directors' remuneration | £858,940 | £915,468 | £996,400 | +8.8% | |
| Directors' pension contributions | £13,973 | £11,133 | £10,498 | -5.7% |
Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. The Δ column is the change from the prior filed period as a percentage of |prior|; lines a company doesn't report show —. About these numbers
Ratios
Computed from the line items above — sparklines read oldest → newest
| Ratio | Trend | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Operating margin | — | — | -90.3% | |
| Net margin | — | — | -62.7% | |
| Return on capital employed | -74.3% | -53.1% | -49.8% | |
| Gearing (liabilities / total assets) | 11.2% | 37.7% | 31.4% | |
| Current ratio | 8.52x | 3.24x | 3.39x | |
| Interest cover | — | — | -75.84x |
Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Margin ratios are hidden where reported turnover is too small relative to profit to yield a meaningful figure — typical of holding companies whose income is mostly subsidiary dividends rather than trading revenue. Sector-distribution context coming next.
Name history
Renamed 1 time since incorporation
- AVIADOBIO LTD 2021-12-02 → present
- NEUROGENEUS LTD 2019-12-20 → 2021-12-02
Audit & accounting basis
- Accounting basis
- IFRS
- Reporting scope
- Consolidated group
- Auditor
- BDO LLP
- Audit opinion
- Unqualified (clean)
- Going concern
- Material uncertainty disclosed
“As the group and parent company are reliant on further funding which is not secured this indicates the existence of a material uncertainty which may cast significant doubt over the group and parent company's ability to continue as going concerns”
Group structure
- AVIADOBIO LTD · parent
- Neurogeneus Ltd (formerly AviadoBio Ltd) 100%
- AviadoBio Inc. 100%
Significant events
- “In March 2026, AviadoBio has secured a strategic investment from The Alzheimer's Drug Discovery Foundation (ADDF) and The Association for Frontotemporal Degeneration (AFTD) through their Treat FTD Fund to support ASPIRE-FTD Trial.”
- “In April 2026, AviadoBio has announced a licensing agreement for Apertura's TfR1 CapX, a novel, intravenously-delivered AAV capsid designed to target human transferrin receptor 1 (hTfR1), cross the blood-brain barrier, and enable broad distribution to the brain and spinal cord.”
Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers
People
9 active · 4 resigned
| Name | Role | Appointed | Born | Nationality |
|---|---|---|---|---|
| BARKER, Laurence Daniel Paul | Director | 2020-09-11 | Jun 1972 | British |
| DESCHAMPS, Lisa | Director | 2021-11-22 | Apr 1971 | American |
| FUNNELL, Timothy Michael, Dr | Director | 2021-11-26 | Oct 1986 | British |
| GOATER, James Jeffrey | Director | 2023-02-01 | Aug 1975 | American |
| LOPEZ, Julio Cesar | Director | 2026-03-20 | Sep 1990 | American |
| MACLAUGHLIN, Fiona Caroline, Dr | Director | 2022-08-26 | Apr 1971 | British |
| SALZMAN, Amber | Director | 2021-09-06 | Nov 1961 | American |
| SCHMIDT, Dominic, Dr | Director | 2022-09-01 | Feb 1982 | British,German |
| SINHA, Nihal | Director | 2020-09-11 | Aug 1984 | British |
Show 4 resigned officers
| Name | Role | Appointed | Resigned |
|---|---|---|---|
| BOLGER, Jeanne Elizabeth, Dr | Director | 2020-09-11 | 2022-08-26 |
| MALIK, Shahzad | Director | 2020-09-11 | 2022-09-01 |
| MCAVINEY, Matthew Douglas | Director | 2021-11-23 | 2026-03-20 |
| SHAW, Christopher Edward Dennistoun | Director | 2019-12-20 | 2020-09-11 |
Ownership
Persons with significant control
| Name | Kind | Nature of control | Notified | Status |
|---|---|---|---|---|
| Kings College London | Corporate entity | Shares 25–50%, Voting 25–50% | 2020-09-11 | Ceased 2021-12-03 |
| Lifearc | Corporate entity | Significant influence | 2020-09-11 | Ceased 2021-12-03 |
| Dementia Discovery General Partner Llp | Corporate entity | Significant influence | 2020-09-11 | Ceased 2021-12-03 |
| Advent Life Sciences Llp | Corporate entity | Significant influence | 2020-09-11 | Ceased 2021-12-03 |
| Johnson & Johnson | Corporate entity | Significant influence | 2020-09-11 | Ceased 2021-12-03 |
| Christopher Edward Dennistoun Shaw | Individual | Shares 50–75%, Voting 50–75% | 2019-12-20 | Ceased 2020-09-11 |
Filing timeline
Last 20 of 93 total filings
Material constitutional events — rename, articles re-file, resolution
- 2026-04-24 RESOLUTIONS Resolution
- 2025-09-02 RP04SH01 Legacy PDF
- 2024-10-27 MA Memorandum articles
- 2024-10-27 RESOLUTIONS Resolution
| Date | Type | Category | Description | |
|---|---|---|---|---|
| 2026-09-18 | AA | accounts | Accounts with accounts type group | |
| 2026-09-07 | SH01 | capital | Capital allotment shares | |
| 2026-04-24 | RESOLUTIONS | resolution | Resolution | |
| 2026-04-21 | SH01 | capital | Capital allotment shares | |
| 2026-04-08 | SH01 | capital | Capital allotment shares | |
| 2026-04-01 | AP01 | officers | Appoint person director company with name date | |
| 2026-04-01 | TM01 | officers | Termination director company with name termination date | |
| 2026-02-25 | SH01 | capital | Capital allotment shares | |
| 2025-12-19 | CS01 | confirmation-statement | Confirmation statement with updates | |
| 2025-11-27 | SH01 | capital | Capital allotment shares | |
| 2025-09-02 | RP04SH01 | change-of-name | Legacy | |
| 2025-08-28 | SH01 | capital | Capital allotment shares | |
| 2025-07-31 | AA | accounts | Accounts with accounts type group | |
| 2025-06-19 | SH01 | capital | Capital allotment shares | |
| 2025-05-13 | MR01 | mortgage | Mortgage create with deed with charge number charge creation date | |
| 2024-12-30 | CS01 | confirmation-statement | Confirmation statement with updates | |
| 2024-11-29 | AA | accounts | Accounts with accounts type small | |
| 2024-11-04 | SH01 | capital | Capital allotment shares | |
| 2024-10-27 | MA | incorporation | Memorandum articles | |
| 2024-10-27 | RESOLUTIONS | resolution | Resolution |
Public-record activity
Raw counts from Companies House — last 12–24 months
- Filings
- 10
- Capital events
- 8
- Officers appointed
- 1
- Officers resigned
- 1
last 12 months
last 24 months
last 12 months
last 12 months
Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.